GET DAILY SIGNALSSUPN Falls -30% After Indivior Merger: What the Repricing Means for Investors
Key Takeaways
- SUPN declined roughly 30% over the past 30 days, from about $42.38 to around $29.80, with the sharpest move tied to the completion of its merger with Indivior.
- The all-stock transaction left legacy Supernus shareholders holding about 43.5% of the combined company, while Indivior holders received a pre-close dividend funded in part by new debt.
- Record Q3 2026 results — revenue of $226.8 million (up 18.1% year over year) and adjusted EPS of $0.88 — did not offset the post-merger repricing.
- Over the trailing three months, the stock has fallen about 35% from the mid-$40s as a steady downtrend accelerated in early November.
- Core growth brands Qelbree, ZURZUVAE, ONAPGO, and GOCOVRI continue to expand, and management is targeting $125 million in annual cost synergies.
- For additional detail on valuation and expectations, explore SUPN's Price Targets, Earnings, and Forecast pages.
- Traders can also review the Trending AI Robots section for current AI-driven strategies.
Supernus Pharmaceuticals (SUPN) and Its Position in CNS Therapies
Supernus Pharmaceuticals is a Rockville, Maryland-based biopharmaceutical company focused on developing and commercializing treatments for central nervous system (CNS) diseases. Its marketed portfolio includes Qelbree for attention-deficit hyperactivity disorder (ADHD), GOCOVRI for dyskinesia in Parkinson's disease, Oxtellar XR and Trokendi XR for epilepsy, APOKYN and XADAGO for Parkinson's disease, MYOBLOC for cervical dystonia and chronic sialorrhea, ONAPGO for motor fluctuations in advanced Parkinson's disease, and ZURZUVAE for postpartum depression through a collaboration with Biogen. Investors follow the stock for its expanding CNS franchise, prescription growth in key brands, and a pipeline of earlier-stage neuroscience candidates. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
SUPN Stock Price Performance Over the Last 30 Days and Quarter
Over the last 30 days, SUPN fell from roughly $42.38 to about $29.80, a decline of approximately 29.7%. The move was not gradual: shares traded mostly in the low $40s through late October before dropping sharply in the first sessions of November as the merger closed.
The trailing three-month picture is similar in direction but larger in magnitude. Beginning August near the mid-$40s, the stock drifted lower through September and October and then accelerated downward into early November, leaving it down roughly 35% over the period. The 52-week range of $37.54 to $59.68 underscores how far the stock has retraced from earlier highs.
The Merger Catalyst Behind the Recent SUPN Decline
The dominant catalyst was the completion of Supernus's all-stock merger with Indivior, announced as closed on November 2, 2026. The combined company, renamed Supernus, Inc., began trading under the SUPN ticker on November 3, with legacy Supernus shareholders owning approximately 43.5% of the enlarged entity.
The deal's capital structure weighed heavily on sentiment. Indivior shareholders received a pre-close cash dividend reported at roughly $1 billion, funded in part by about $650 million in new debt placed on the combined company — while Supernus shareholders did not receive that dividend. The resulting dilution and added leverage triggered a sharp repricing of the stock, which outweighed otherwise strong operating results.
Fundamental news was positive during the same window. On October 29, Supernus reported record third-quarter revenue of $226.8 million, up 18.1% year over year, with adjusted EPS of $0.88 versus roughly $0.49 consensus, and raised full-year 2026 revenue guidance to a range of $875 million to $900 million. The company also announced that the FDA granted ONAPGO seven years of orphan drug exclusivity. Separately, Supernus was replaced by Huron Consulting Group in the S&P SmallCap 600 index effective in early November, a change that can generate index-driven selling pressure.
Broader Trends Driving SUPN Performance Over the Quarter
Beyond the merger, the quarter reflected a longer-standing disconnect between improving fundamentals and a declining share price. Throughout August and September, the stock trended lower even as Qelbree prescriptions grew 18% year over year, ZURZUVAE collaboration revenue advanced, and ONAPGO recovered from earlier supply constraints. Investors also weighed the intangible asset impairment charges the company affirmed for full-year 2026, along with the uncertain economics of the pending Indivior combination.
The broader narrative over the quarter was one of a growing, profitable CNS franchise that nonetheless faced a structurally dilutive and debt-funded merger, culminating in the sharp early-November re-rating. Management's $125 million annual synergy target and the expanded combined portfolio represent the primary integration goals investors are now watching.
Key Drivers for the SUPN Stock Forecast Ahead
Going forward, investors are likely to focus on the integration of Supernus and Indivior, including the realization of the $125 million cost-synergy target and the combined entity's capital structure following the added debt. Clarity on the enlarged company's full-year 2027 guidance, expected in early 2027, is a key milestone. Continued prescription momentum in Qelbree, ZURZUVAE, ONAPGO, and GOCOVRI, along with pipeline progress on candidates such as SPN-820 and SPN-817, will also shape sentiment. Analyst consensus remains a Buy with an average price target of $60.50, though investors should weigh that against the post-merger share count, leverage, and execution risks. From what I see, this is important because execution on synergies will likely set the tone for the next several quarters.
Using Tickeron AI Tools in My Research
In my own analysis of names like SUPN, I often turn to Tickeron’s platform for additional perspective. The AI Trading Bots section has been particularly useful for reviewing automated strategies that align with current market conditions, helping me cross-check signals without replacing my own due diligence. It provides a practical way to see how different approaches perform across a range of tickers and timeframes.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
SUPN's RSI Indicator climbs out of oversold territory
The RSI Oscillator for SUPN moved out of oversold territory on October 19, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 26 similar instances when the indicator left oversold territory. In 22 of the 26 cases the stock moved higher. This puts the odds of a move higher at 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 46 of 61 cases where SUPN's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.
The Momentum Indicator moved above the 0 level on October 28, 2026. You may want to consider a long position or call options on SUPN as a result. In 77 of 97 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.
The Moving Average Convergence Divergence (MACD) for SUPN just turned positive on October 22, 2026. Looking at past instances where SUPN's MACD turned positive, the stock continued to rise in 36 of 49 cases over the following month. The odds of a continued upward trend are 73%.
Following a +2.04% 3-day Advance, the price is estimated to grow further. Considering data from situations where SUPN advanced for three days, in 224 of 312 cases, the price rose further within the following month. The odds of a continued upward trend are 72%.
SUPN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SUPN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 64%.
The Aroon Indicator for SUPN entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 24 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.367) is normal, around the industry mean (8.029). P/E Ratio (-21.833) is within average values for comparable stocks, (-0.853). Projected Growth (PEG Ratio) (0.900) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.047) among similar stocks. P/S Ratio (2.863) is also within normal values, averaging (178.797).
The Tickeron Profit vs. Risk Rating rating for this company is 53 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 70 (best 1 - 100 worst), indicating slightly worse than average price growth. SUPN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer for the treatment of central nervous system
Industry PharmaceuticalsGeneric
Advertisement